by Clinical Neuropsychologist Online | Tuesday, September 15, 2026 | Dementia
Abstract INTRODUCTION Our goal was to determine Alzheimer’s disease (AD) and related dementias (ADRD) incidence and risk factors among American Indian and Alaska Native (AI/AN) veterans, an understudied group. METHODS We identified AI/AN veterans ≥ 55 years...
by Clinical Neuropsychologist Online | Sunday, September 13, 2026 | Dementia
Abstract INTRODUCTION Postmenopausal estrogen decline may contribute to Alzheimer’s disease (AD), but evidence linking circulating estrogens to cerebrospinal fluid (CSF) AD biomarkers remains limited. METHODS We analyzed 854 female participants from the European...
by Clinical Neuropsychologist Online | Sunday, September 13, 2026 | Dementia
Abstract INTRODUCTION Vascular cognitive impairment and dementia (VCID) is a common cause of cognitive impairment, yet validated biomarkers, particularly those reflecting vascular function, remain lacking. Oxygen extraction fraction (OEF), which reflects the...
by Clinical Neuropsychologist Online | Saturday, September 12, 2026 | Dementia
Abstract INTRODUCTION Late-onset Alzheimer’s disease (LOAD) and major depressive disorder (MDD) share genetic etiologies. Here, we investigated brain transcriptomic landscapes to gain insights into shared and divergent molecular and biological etiologies across...
by Clinical Neuropsychologist Online | Saturday, September 12, 2026 | Dementia
Abstract INTRODUCTION Fluorodeoxyglucose (FDG) positron emission tomography (PET) is widely used for detecting metabolic changes associated with neurodegeneration in Alzheimer’s disease (AD) and other dementias but is costly and involves ionizing radiation. Here...
